Cipla said that the US FDA has issued six observations following the inspection conducted in August 2022 at its Goa plant.
The drug maker said that the Goa plant recently underwent a United States Food and Drug Administration (US FDA) inspection from 16th - 26th August 2022. The US FDA had inspected the company's Goa manufacturing facility in September 2019. A warning letter for the same was received by the company in February 2020.
Cipla further informed that on conclusion of the inspection, the company has now received 6 observations with some referencing to the observations made during the September 2019 inspection. There are no data integrity observations.
"The company will work closely with the US FDA and is committed to address these within the stipulated time, Cipla said in a statement.
Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets.
The company's consolidated net profit slipped 4% to Rs 686.40 crore on 2.3% decline in total revenue from operations to Rs 5,375.19 crore in Q1 FY23 over Q1 FY22.
The scrip declined 0.51% to end at Rs 1020.25 on the BSE on Friday.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app